Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
In the last 90 days, Cadrenal Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Cadrenal Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +3 vs. Q2 2025
- Shares held
- 114.2K
- +45.8K (+67.0%) vs. Q2 2025
- Total value
- $1.57M
- +$750.5K (+91.1%) vs. Q2 2025
- New holders
- 5
- 3 more added
- Sold out
- 2
- 3 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CVKD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $379.6K |
| Q1 2026 | 20 | $460.1K |
| Q4 2025 | 20 | $823.9K |
| Q3 2025 | 20 | $1.57M |
| Q2 2025 | 17 | $823.9K |
| Q1 2025 | 16 | $1.22M |
| Q4 2024 | 10 | $215.5K |
| Q3 2024 | 2 | $68 |
| Q2 2024 | 9 | $165.0K |
| Q1 2024 | 10 | $1.04M |
| Q4 2023 | 6 | $407.5K |
| Q3 2023 | 9 | $751.9K |
| Q2 2023 | 3 | $429 |
| Q1 2023 | 3 | $1.34K |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Cadrenal Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 54,239 | $747.1K | 0.00% | +5,644+11.6% | Added |
| Citadel Advisors LLC | 19,864 | $273.6K | 0.00% | +19,864 | New |
| LPL Financial LLC | 14,200 | $196.4K | 0.00% | +14,200 | New |
| Geode Capital Management, LLC | 12,710 | $175.1K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 7,500 | $103.3K | 0.00% | +7,500 | New |
| BlackRock, Inc. | 3,378 | $46.7K | 0.00% | +96+2.9% | Added |
| Morgan Stanley | 880 | $12.2K | 0.00% | +450+104.7% | Added |
| Advisor Group Holdings, Inc. | 500 | $6.48K | 0.00% | 00.0% | Unchanged |
| Rockefeller Capital Management L.P. | 300 | $4.15K | 0.00% | +300 | New |
| Jones Financial Companies LLLP | 172 | $2.41K | 0.00% | 00.0% | Unchanged |
| Clearstead Advisors, LLC | 150 | $2.08K | 0.00% | +150 | New |
| Harbour Investments, Inc. | 100 | $1.38K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 99 | $1.37K | 0.00% | −1−1.0% | Reduced |
| UBS Group AG | 35 | $484 | 0.00% | −291−89.3% | Reduced |
| Archer Investment Corp | 35 | $484 | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 30 | $415 | 0.00% | 00.0% | Unchanged |
| Farther Finance Advisors, LLC | 25 | $346 | 0.00% | 00.0% | Unchanged |
| Carolina Wealth Advisors, LLC | 20 | $277 | 0.00% | 00.0% | Unchanged |
| Caldwell Sutter Capital, Inc. | 5 | $69 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1 | $14 | 0.00% | −13−92.9% | Reduced |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −1,917−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −136−100.0% | Sold out |